Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study

被引:5
|
作者
Giedraitiene, N. [1 ]
Taluntiene, V [1 ]
Kaubrys, G. [1 ]
机构
[1] Vilnius Univ, Fac Med, Inst Clin Med, Clin Neurol & Neurosurg, Vilnius, Lithuania
关键词
RESOURCE UTILIZATION; PERSISTENCE; IMPACT; FINGOLIMOD; REVISIONS; RELAPSE; COSTS; DRUG;
D O I
10.1038/s41598-022-16790-3
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Less than half of patients with chronic diseases, including multiple sclerosis (MS), adhere to their prescribed medications. Treatment selection is essential for patient adherence. The aim of this study was to explore the potential factors influencing nonadherence to disease-modifying therapies (DMTs) in MS. This prospective, cross-sectional study was performed at the Multiple Sclerosis Center between 2018 and 2021. In total, 85 patients were eligible for final analysis. Forty-one patient (48.2%) with MS were non-adherent to DMT. Male sex, oral administration of drugs, and longer treatment duration were associated with nonadherence. The mean Expanded Disability Status Scale score did not differ between the adherent and non-adherent patients (p > 0.05). Patients with a higher score on the Symbol Digit Modalities Test, who were receiving self-injection therapy, had shorter treatment duration, and higher disability, were more likely to be adherent to DMT than those without. To minimize nonadherence in patients with MS, the patient's information processing speed should be considered before DMT initiation, and appropriate treatment options should be discussed.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study
    N. Giedraitiene
    V. Taluntiene
    G. Kaubrys
    Scientific Reports, 12
  • [2] Relationship between severe relapses and adherence to disease-modifying therapy in multiple sclerosis patients
    Meletiche, D.
    Kozma, C.
    Bennett, R.
    AL-Sabbagh, A.
    JOURNAL OF NEUROLOGY, 2008, 255 : 205 - 205
  • [3] Disease-modifying therapy aids cognition in multiple sclerosis
    Amato, Maria Pia
    Krupp, Lauren B.
    NATURE REVIEWS NEUROLOGY, 2020, 16 (10) : 525 - 526
  • [4] Disease-modifying therapy aids cognition in multiple sclerosis
    Maria Pia Amato
    Lauren B. Krupp
    Nature Reviews Neurology, 2020, 16 : 525 - 526
  • [5] Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy
    Thannhauser, Jennifer E.
    Mah, Jean K.
    Metz, Luanne M.
    PEDIATRIC NEUROLOGY, 2009, 41 (02) : 119 - 123
  • [6] Patient choice and adherence with disease-modifying therapy in multiple sclerosis
    Burke, G
    Pozo, A
    Nairne, A
    Birmingham, H
    Gregory, R
    Palace, JA
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S189 - S189
  • [7] Factors that influence adherence with disease-modifying therapy in multiple sclerosis
    Treadaway, KD
    Brannon, KD
    Morrison, A
    Remington, GM
    Olek, M
    Racke, MK
    Frohman, EM
    NEUROLOGY, 2006, 66 (05) : A30 - A30
  • [8] Factors that influence adherence with disease-modifying therapy in multiple sclerosis
    Treadaway, K
    Hawker, K
    Racke, M
    Brannon, K
    Morrison, A
    Remington, G
    Frohman, E
    Cohen, B
    Corboy, J
    Simsarian, J
    Lynch, S
    Jeffery, D
    MULTIPLE SCLEROSIS, 2005, 11 : S158 - S158
  • [9] Characteristics of Poor Adherence to the Injectable Disease-Modifying Therapies in Multiple Sclerosis: A Cross-Canada Prospective Study
    McKay, Kyla
    Tremlett, Helen
    Fisk, John
    Patten, Scott
    Fiest, Kirsten
    Berrigan, Lindsay
    Campbell, Trudy
    Marrie, Ruth-Ann
    NEUROLOGY, 2016, 86
  • [10] Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
    McKay, Kyla A.
    Tremlett, Helen
    Patten, Scott B.
    Fisk, John D.
    Evans, Charity
    Fiest, Kirsten
    Campbell, Trudy
    Marrie, Ruth Ann
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (04) : 588 - 596